Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study

Canadian Journal of Cardiology

Volumn 32, Issue 8, 2016, Pages 986.e17-986.e22

  Harel, Ziv ^a,b,c   Mamdani, Muhammad ^b,c   Juurlink, David N ^c,d   Garg, Amit X ^c,e   Wald, Ron ^a,b   Yao, Zhan ^c   Gomes, Tara ^b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; DABIGATRAN; RIVAROXABAN; SEROTONIN UPTAKE INHIBITOR; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GROUPS BY AGE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ODDS RATIO; POPULATION BASED CASE CONTROL STUDY; RISK; RISK ASSESSMENT; SENSITIVITY ANALYSIS; VERY ELDERLY; AGE; CASE CONTROL STUDY; CHEMICALLY INDUCED; HEMORRHAGE; ONTARIO; RENAL INSUFFICIENCY, CHRONIC;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CASE-CONTROL STUDIES; DABIGATRAN; FEMALE; HEMORRHAGE; HUMANS; MALE; ONTARIO; RENAL INSUFFICIENCY, CHRONIC; RISK; RIVAROXABAN; WARFARIN;

EID: 84960862119     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2016.01.013     Document Type: Article

References (34)

1. 1 Cohen, D., Dabigatran: how the drug company withheld important analyses. BMJ, 349, 2014, g4670.
2. 2 Harder, S., Graff, J., Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 69 (2013), 1617–1633.
3. 3 Couser, W.G., Remuzzi, G., Mendis, S., Tonelli, M., The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 80 (2011), 1258–1270.
4. 4 Nelson, S.E., Shroff, G.R., Li, S., Herzog, C.A., Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in Medicare patients. J Am Heart Assoc, 1, 2012, e002097.
5. 5 Mahmoodi, B.K., Gansevoort, R.T., Naess, I.A., et al. Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation 126 (2012), 1964–1971.
6. 6 Xu, Y., Holbrook, A.M., Simpson, C.S., Dowlatshahi, D., Johnson, A.P., Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ Open 1 (2013), E115–E119.
7. 7 FDA approved drug products: label information for PRADAXA. 2012 Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022512s009lbl.pdf. Accessed August 12, 2014.
8. 8 FDA approved drug products: Xarelto. 2012 Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022406s001s002s003lbl.pdf. Accessed August 12, 2014.
9. 9 Health Canada: Drugs and Health Products: Pradax. 2012 Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drugmed/ sbd_smd_2008_pradax_114887-eng.php. Accessed August 12, 2014.
10. 10 Health Canada: Drugs and Health Products: Xarelto. 2012 Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2009_xarelto_119111-eng.php. Accessed August 12, 2014.
11. 11 European Medicines Agency, Product Information: Pradaxa. 2012 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed August 12, 2014.
12. 12 European Medicines Agency. Product Information: Xarelto. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed August 12, 2014.
13. 13 Fellows, S.E., Rosini, J.M., Curtis, J.A., Volz, E.G., Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency. J Emerg Med 44 (2013), e221–e225.
14. 14 Wychowski, M.K., Kouides, P.A., Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother, 46, 2012, e10.
15. 15 von Elm, E., Altman, D.G., Egger, M., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147 (2007), 573–577.
16. 16 Gomes, T., Mamdani, M.M., Holbrook, A.M., et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ 185 (2013), E121–E127.
17. 17 Gilbert, C.J., Gomes, T., Mamdani, M.M., et al. No increase in adverse events during aliskiren use among Ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers. Can J Cardiol 29 (2013), 586–591.
18. 18 Fleet, J.L., Dixon, S.N., Shariff, S.Z., et al. Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. BMC Nephrol, 14, 2013, 81.
19. 19 Arnason, T., Wells, P.S., van Walraven, C., Forster, A.J., Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 118 (2006), 253–262.
20. 20 Pang, D., A relative power table for nested matched case-control studies. Occup Environ Med 56 (1999), 67–69.
21. 21 Hijazi, Z., Hohnloser, S.H., Oldgren, J., et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 129 (2014), 961–970.
22. 22 Fox, K.A.A., Piccini, J.P., Wojdyla, D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32 (2011), 2387–2394.
23. 23 Harel, Z., Sholzberg, M., Shah, P.S., et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 25 (2014), 431–442.
24. 24 Sardar, P., Chatterjee, S., Herzog, E., et al. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol 30 (2014), 888–897.
25. 25 Miyares, M.A., One-year risk of bleeding with dabigatran in patients with atrial fibrillation: placing real-world results into perspective. JAMA Intern Med 175 (2015), 1242–1243.
26. 26 Southworth, M.R., Reichman, M.E., Unger, E.F., Dabigatran and postmarketing reports of bleeding. N Engl J Med 368 (2013), 1272–1274.
27. 27 Charlton, B., Redberg, R., The trouble with dabigatran. BMJ, 349, 2014, g4681.
28. 28 Harper, P., Young, L., Merriman, E., Bleeding risk with dabigatran in the frail elderly. N Engl J Med 366 (2012), 864–866.
29. 29 Hernandez, I., Baik, S.H., Pinera, A., Zhang, Y., Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 175 (2015), 18–24.
30. 30 Lafrance, J.P., Djurdjev, O., Levin, A., Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort. Nephrol Dial Transplant 25 (2010), 2203–2209.
31. 31 Siegal, D.M., Crowther, M.A., Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 34 (2013), 489–498b.
32. 32 Schulman, S., Beyth, R.J., Kearon, C., Levine, M.N., Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 (2008), 257s–298s.
33. 33 Liu, S., Kim, C.O., Lucyk, S.N., Dosage of dabigatran as a risk factor for bleeding in atrial fibrillation. JAMA Intern Med 175 (2015), 1244–1245.
34. 34 Verma, A., Cairns, J.A., Mitchell, L.B., et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of Atrial Fibrillation. Can J Cardiol 30 (2014), 1114–1130.